EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile



Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile



Glycobiology 18(9): 698-706



The biological and ligand-binding properties of recombinant C-terminal cell-binding domains (CBDs) and subdomains of the two large exotoxins, Toxin A (TcdA) and Toxin B (TcdB) expressed by Clostridium difficile were examined in the hemagglutination and Verocytotoxicity neutralization assays and by qualitative affinity chromatography using Sepharose-linked alpha Gal(1,3)betaGal(1,4)beta Glc as well as the direct electrospray ionization mass spectrometry (ES-MS) assay. These studies revealed that, whereas the full-length TcdA CBD agglutinated rabbit erythrocytes, neutralized TcdA-mediated Vero cell death and bound to alpha Gal(1,3)betaGal(1,4)beta Glc-derivatized Sepharose, the TcdB CBD was inactive in these functional assays. Moreover, retention by alpha Gal(1,3)betaGal(1,4)beta Glc-derivatized Sepharose corresponded to the number of available TcdA subdomain ligand-binding sites. By contrast, the ES-MS assays revealed that both the TcdA and TcdB CBD bind to 8-methoxycarbonyloctyl-alpha Gal(1,3)betaGal(1,4)beta Glc sequences with similar avidities. Additional ES-MS experiments using chemically altered alpha Gal(1,3)betaGal(1,4)beta Glc sequences also revealed that the TcdA and TcdB CBD will tolerate a fair amount of structural variation in their complementary glycan ligands. Although the studies are consistent with the known ligand-binding properties of the TcdA and TcdB holotoxins, they also revealed subtle heretofore unrecognized functional differences in their receptor recognition properties.

(PDF emailed within 0-6 h: $19.90)

Accession: 053328343

Download citation: RISBibTeXText

PMID: 18509107

DOI: 10.1093/glycob/cwn048



Related references

Overexpression of the Endosomal Anion/Proton Exchanger ClC-5 Increases Cell Susceptibility toward Clostridium difficile Toxins TcdA and TcdB. Frontiers in Cellular and Infection Microbiology 7: 67-67, 2017

Lectin activity of the TcdA and TcdB toxins of Clostridium difficile. Infection and Immunity 2018, 2018

Clostridium difficile Toxins TcdA and TcdB Cause Colonic Tissue Damage by Distinct Mechanisms. Infection and Immunity 84(10): 2871-2877, 2017

Sequence variation in tcdA and tcdB of Clostridium difficile: ST37 with truncated tcdA is a potential epidemic strain in China. Journal of Clinical Microbiology 52(9): 3264-3270, 2015

Release of TcdA and TcdB from Clostridium difficile cdi 630 is not affected by functional inactivation of the tcdE gene. Microbial Pathogenesis 52(1): 92-100, 2012

The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. FEMS Microbiology Letters 155(1): 45-54, 1997

Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections. Mbio 6(3): E00551-E00551, 2016

Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA- tcdB+ C. difficile prevalent area. Anaerobe 15(6): 266-269, 2010

CdtR Regulates TcdA and TcdB Production in Clostridium difficile. Plos Pathogens 12(7): E1005758-E1005758, 2017

A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile. Bmc Infectious Diseases 16(1): 596-596, 2016

Detection and transcriptional analysis of tcdA and tcdB in a non-toxigenic strain of Clostridium difficile. Abstracts of the General Meeting of the American Society for Microbiology 99: 45-46, 1999

TcdB or not TcdB: a tale of two Clostridium difficile toxins. Future Microbiology 6(2): 121-123, 2011

Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. Journal of Infectious Diseases 207(2): 323-330, 2013

Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface. Journal of Biological Chemistry 292(35): 14401-14412, 2017

A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. Journal of Infectious Diseases 210(6): 964-972, 2014